Ellen Kilger
Tuebingen, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Safety and neuroprotective efficacy of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo study.
Journal: BMC medicine
Published: August 22, 2025
Ocular delivery of different valosin-containing protein (VCP) inhibitory formulations prevents retinal degeneration in rho∆I255 mice.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: July 08, 2025
The AMD-associated genetic polymorphism CFH Y402H confers vulnerability to Hydroquinone-induced stress in iPSC-RPE cells.
Journal: Frontiers in immunology
Published: November 12, 2024
Mutant dominant-negative rhodopsin∆I256 causes protein aggregates degraded via ERAD and prevents normal rhodopsin from proper membrane trafficking.
Journal: Frontiers in molecular biosciences
Published: January 11, 2024
mTOR Inhibition via Rapamycin Treatment Partially Reverts the Deficit in Energy Metabolism Caused by FH Loss in RPE Cells.
Journal: Antioxidants (Basel, Switzerland)
Published: October 29, 2021
CFH Loss in Human RPE Cells Leads to Inflammation and Complement System Dysregulation via the NF-κB Pathway.
Journal: International journal of molecular sciences
Published: June 18, 2021
Loss of Complement Factor H impairs antioxidant capacity and energy metabolism of human RPE cells.
Journal: Scientific reports
Published: January 15, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026